Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Reminyl new Rxs top 10% share

Executive Summary

Reminyl (galantamine) has "new Rx share hitting levels of over 10.4%" since its early May launch, J&J Worldwide Pharmaceuticals Chair Christine Poon tells Bear Stearns conference call Sept. 26. "The introduction of Reminyl has taken some of the steam off [Pfizer's/Eisai's] Aricept and [Novartis'] Exelon," Novartis Pharmaceuticals CEO Paulo Costa conceded during a separate Sept. 25 call. "Both products have been similarly impacted," Costa suggests, noting that Exelon's "new Rx market share is still fairly high at 21%"
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS038593

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel